Kane Biotech (TSXV:KNE) has completed a major transformation during the past year, relaunching its animal health business, expanding into human health, raising non-dilutive financing, and hiring a new executive team...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Hepion advances to next dosing level in ongoing Phase 1 study of CRV431
Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the next higher dose of CRV431 in its ongoing Phase 1 multiple ascending dose trial in healthy volunteers. The clinical trial management team determined the 75 mg dosing...
Tonix Pharmaceuticals enrolls first patient in Phase 3 fibromyalgia study
Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first patient in its Phase 3 study of TNX-102 SL for the management of fibromyalgia. TNX-102 SL is a non-opioid analgesic, administered daily at bedtime. The trial will...
Dermira atopic dermatitis drug gets FDA fast track designation
Dermira’s (NASDAQ:DERM) lebrikizumab received FDA fast track designation for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab is a humanized monoclonal antibody that targets interleukin-13, which is...
Analysts raise Forty Seven price targets on 5F9 data
Analysts for H.C. Wainwright and BTIG raised their price targets for Forty Seven (NASDAQ:FTSV) after the company updated results from its ongoing Phase 1b clinical study of magrolimab (5F9) in combination with...
Hepion to present CRV431 clinical and scientific updates at HEP DART 2019 meeting
Hepion Pharmaceuticals (NASDAQ:HEPA) is slated to present two posters at the HEP DART 2019, frontiers in drug development for hepatology, including viral hepatitis, NASH and co-infections meeting. The presentations...
ObsEva reports positive results from Phase 3 study of linzagolix
ObsEva’s (NASDAQ:OBSV) Phase 3 trial of linzagolix for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids met its primary and secondary endpoints. The U.S. trial enrolled 535 women to evaluate the...
FDA removes hold on Abeona’s pivotal gene therapy trial
The FDA removed its clinical hold on Abeona Therapeutics’ (NASDAQ:ABEO) Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The hold was removed following...
WB ups Diplomat Pharmacy to market perform
William Blair upgraded Diplomat Pharmacy (NYSE:DPLO) to “market perform” from “underperform” after UnitedHealth Group’s (NYSE:UNH) OptumRx agreed to acquire Diplomat for $4 a share. Shares of Diplomat were quoted at $3...
Musculoskeletal company Trainer Rx changes name to RecoveryOne
Closely-held RecoveryOne, formerly Trainer Rx, which is focused on enabling patient recovery from musculoskeletal (MSK) conditions, is raising $12-million in a round led by Cigna Ventures. The company says the financing...
Just a few of the companies we’ve highlighted along the way
